Cargando…

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation

Oral antifungal prophylaxis with extended-spectra azoles is widely used in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT), while controlled studies for oral antifungal prophylaxis after bone marrow transplantation in children are not available. This survey analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Döring, M., Blume, O., Haufe, S., Hartmann, U., Kimmig, A., Schwarze, C.-P., Lang, P., Handgretinger, R., Müller, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953550/
https://www.ncbi.nlm.nih.gov/pubmed/24173819
http://dx.doi.org/10.1007/s10096-013-1998-2
_version_ 1782307377656102912
author Döring, M.
Blume, O.
Haufe, S.
Hartmann, U.
Kimmig, A.
Schwarze, C.-P.
Lang, P.
Handgretinger, R.
Müller, I.
author_facet Döring, M.
Blume, O.
Haufe, S.
Hartmann, U.
Kimmig, A.
Schwarze, C.-P.
Lang, P.
Handgretinger, R.
Müller, I.
author_sort Döring, M.
collection PubMed
description Oral antifungal prophylaxis with extended-spectra azoles is widely used in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT), while controlled studies for oral antifungal prophylaxis after bone marrow transplantation in children are not available. This survey analyzed patients who had received either itraconazole, voriconazole, or posaconazole. We focused on the safety, feasibility, and initial data of efficacy in a cohort of pediatric patients and adolescents after high-dose chemotherapy and HSCT. Fifty consecutive pediatric patients received itraconazole, 50 received voriconazole, and 50 pediatric patients received posaconazole after HSCT as oral antifungal prophylaxis. The observation period lasted from the start of oral prophylactic treatment with itraconazole, voriconazole, or posaconazole until two weeks after terminating the oral antifungal prophylaxis. No incidences of proven or probable invasive mycosis were observed during itraconazole, voriconazole, or posaconazole treatment. A total of five possible invasive fungal infections occurred, two in the itraconazole group (4 %) and three in the voriconazole group (6 %). The percentage of patients with adverse events potentially related to clinical drugs were 14 % in the voriconazole group, 12 % in the itraconazole group, and 8 % in the posaconazole group. Itraconazole, voriconazole, and posaconazole showed comparable efficacy as antifungal prophylaxis in pediatric patients after allogeneic HSCT.
format Online
Article
Text
id pubmed-3953550
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-39535502014-03-14 Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation Döring, M. Blume, O. Haufe, S. Hartmann, U. Kimmig, A. Schwarze, C.-P. Lang, P. Handgretinger, R. Müller, I. Eur J Clin Microbiol Infect Dis Article Oral antifungal prophylaxis with extended-spectra azoles is widely used in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT), while controlled studies for oral antifungal prophylaxis after bone marrow transplantation in children are not available. This survey analyzed patients who had received either itraconazole, voriconazole, or posaconazole. We focused on the safety, feasibility, and initial data of efficacy in a cohort of pediatric patients and adolescents after high-dose chemotherapy and HSCT. Fifty consecutive pediatric patients received itraconazole, 50 received voriconazole, and 50 pediatric patients received posaconazole after HSCT as oral antifungal prophylaxis. The observation period lasted from the start of oral prophylactic treatment with itraconazole, voriconazole, or posaconazole until two weeks after terminating the oral antifungal prophylaxis. No incidences of proven or probable invasive mycosis were observed during itraconazole, voriconazole, or posaconazole treatment. A total of five possible invasive fungal infections occurred, two in the itraconazole group (4 %) and three in the voriconazole group (6 %). The percentage of patients with adverse events potentially related to clinical drugs were 14 % in the voriconazole group, 12 % in the itraconazole group, and 8 % in the posaconazole group. Itraconazole, voriconazole, and posaconazole showed comparable efficacy as antifungal prophylaxis in pediatric patients after allogeneic HSCT. Springer Berlin Heidelberg 2013-10-31 2014 /pmc/articles/PMC3953550/ /pubmed/24173819 http://dx.doi.org/10.1007/s10096-013-1998-2 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Döring, M.
Blume, O.
Haufe, S.
Hartmann, U.
Kimmig, A.
Schwarze, C.-P.
Lang, P.
Handgretinger, R.
Müller, I.
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title_full Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title_fullStr Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title_full_unstemmed Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title_short Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
title_sort comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953550/
https://www.ncbi.nlm.nih.gov/pubmed/24173819
http://dx.doi.org/10.1007/s10096-013-1998-2
work_keys_str_mv AT doringm comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT blumeo comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT haufes comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT hartmannu comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT kimmiga comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT schwarzecp comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT langp comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT handgretingerr comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation
AT mulleri comparisonofitraconazolevoriconazoleandposaconazoleasoralantifungalprophylaxisinpediatricpatientsfollowingallogeneichematopoieticstemcelltransplantation